InvestorsHub Logo
Followers 120
Posts 20441
Boards Moderated 0
Alias Born 06/13/2011

Re: None

Wednesday, 10/18/2023 11:57:32 AM

Wednesday, October 18, 2023 11:57:32 AM

Post# of 1505
Sold at $4.06. I tend to "sell the news " . May re enter when I see how well patients transition to Xphozah.
The wild card is the EU. Companies like CSL Vifor in the EU usually buy small specialized CKD companies like this as they have a large well established cardio-renal sales force ...so its an easy bolt on.
I expect them to watch sales / patient acceptance for awhile before moving.
This is not investment advice.
Stock will certainly jump on any buy out spec.
I may re enter later following the launch .
Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARDX News